Kevin Patrick Danahy Sells 5,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 5,000 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $23.64, for a total value of $118,200.00. Following the completion of the transaction, the insider owned 43,298 shares of the company’s stock, valued at $1,023,564.72. The trade was a 10.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Kevin Patrick Danahy also recently made the following trade(s):

• On Friday, February 13th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $23.53, for a total value of $470,600.00.
• On Tuesday, February 17th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $23.63, for a total value of $472,600.00.
• On Monday, February 9th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $21.45, for a total transaction of $429,000.00.
• On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $25.20, for a total transaction of $504,000.00.

Pulse Biosciences Stock Performance

Shares of PLSE opened at $18.99 on Wednesday. Pulse Biosciences, Inc has a fifty-two week low of $12.56 and a fifty-two week high of $26.30. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -17.58 and a beta of 1.77. The firm has a 50 day moving average price of $16.57 and a 200-day moving average price of $16.16.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Thursday, February 19th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.06. The business had revenue of ($0.09) million for the quarter, compared to the consensus estimate of $0.23 million.

Hedge Funds Weigh In On Pulse Biosciences

Several hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its stake in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after acquiring an additional 680 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after purchasing an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Pulse Biosciences by 44.0% in the third quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after buying an additional 1,372 shares during the period. KLP Kapitalforvaltning AS grew its holdings in shares of Pulse Biosciences by 136.0% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock worth $104,000 after acquiring an additional 3,400 shares during the period. Finally, AlphaQuest LLC raised its position in shares of Pulse Biosciences by 184.5% in the 2nd quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock worth $134,000 after acquiring an additional 5,748 shares in the last quarter. 76.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PLSE has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Oppenheimer reissued an “outperform” rating and set a $30.00 price objective on shares of Pulse Biosciences in a research note on Friday. Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Mizuho set a $30.00 target price on shares of Pulse Biosciences in a research note on Friday, February 6th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $30.00.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.